Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).
Philip C MackJieling MiaoMary W RedmanJames MoonSarah B GoldbergRoy S HerbstMary Ann MelnickZenta WaltherFred R HirschKaterina PolitiKaren KellyDavid R GandaraPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Plasma clearance of mutant EGFR ctDNA at 8 weeks was highly and significantly predictive of PFS and OS, outperforming RECIST response for predicting long-term benefit.